BioStem Technologies, Inc., a regenerative medicine company specializing in perinatal tissue allograft products, reported its fourth quarter and full year 2025 financial results, revealing a year of significant market pressures offset by strategic moves to diversify and strengthen its business. The company's net revenue for Q4 2025 was $10.1 million, a 55% decrease compared to Q4 2024, primarily attributed to reimbursement uncertainty and competitive pressure in physician office and mobile settings. For the full year 2025, net revenue was $47.5 million, down from $69.7 million in 2024.
Despite the revenue decline, BioStem maintained exceptionally strong gross margins. The company reported a gross profit of $9.8 million, or 97% of net revenue, for Q4 2025, up from 84% in the prior year period. For the full year, gross margin was 94%, compared to 80% in 2024. This margin improvement reflects a product mix shift toward products that do not carry a licensing fee. However, the company reported a GAAP net loss of ($11.3 million) for Q4 2025 and ($6.6 million) for the full year, compared to net income in 2024, driven by lower revenue and higher operating expenses, including a charge for potentially uncollectible accounts receivable.
A key strategic development was the January 2026 acquisition of the BioTissue Holdings Inc. surgical and wound assets. This move significantly expands BioStem's product portfolio and commercial footprint, diversifying its end markets into the hospital setting. The integration includes BioTissue's national sales force of approximately 20 direct sales representatives and managers, plus over 30 independent sales agents. CEO Jason Matuszewski stated the acquisition makes BioStem "a fundamentally stronger and more diversified regenerative medicine company" with increased exposure to commercially insured patient populations, which is critical for navigating the evolving reimbursement landscape.
The company provided a cautious outlook for 2026, anticipating first quarter revenue in the range of $5 million to $6 million. It expects the physician office business to be down significantly from the prior quarter, while the newly acquired hospital business is projected to perform at historical levels. BioStem expects to drive sequential and year-over-year growth in the hospital business in the second half of 2026 after completing integration activities and expanding its salesforce. The company also sees potential for the physician office market to stabilize in the latter half of the year, offering an opportunity for sequential revenue growth improvement.
In corporate developments, BioStem promoted Barry Hasset to Chief Commercial Officer and strengthened its Board of Directors with the appointment of Jodi Ungrodt as Audit Committee Chairperson. The company also appointed KPMG LLP as its independent registered public accounting firm in October 2025 and is working toward audited financial statements for 2024 and 2025, a key step in its pursuit of a Nasdaq uplisting. As of December 31, 2025, cash equivalents totaled $29.5 million, which decreased to approximately $16 million post the BioTissue acquisition closing on January 21, 2026. For more information, visit https://biostemtechnologies.com.
